Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial

Abstract Ecnoglutide is a cAMP-biased GLP-1 analogue developed for the treatment of type 2 diabetes mellitus (T2DM) and obesity. We conducted a randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of ecnoglutide in adults with T2DM inadequately controlled w...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Dalong Zhu, Weimin Wang, Guoyu Tong, Jianhua Ma, Binhong Wen, Xin Zheng, Bimin Shi, Shuguang Pang, Kun Wang, Xiaoxia Shi, Xianghua Zhang, Liujun Fu, Yang Liu, Yibing Lu, Debin Huang, Chengxia Jiang, Tianrong Pan, Haibo Xue, Jie Han, Hongcheng Ding, Shaohui Bing, Feifei Jiang, Qing Zheng, Ming Yang, Lei Guan, Xingquan Liu, Jing Ning, Yue Bu, Mengying Guo, Liu Yang, Wanjun Guo, Yao Li, Susan Xu, Hai Pan
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Nature Portfolio 2026-01-01
Seri Bilgileri:	Nature Communications
Online Erişim:	https://doi.org/10.1038/s41467-025-68165-7
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!